InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q2 2022 Results, Corporate Updates
August 12, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, is reporting financial numbers and clinical program updates for the quarter ended June 30, 2022. Highlights of the report include news that PCSA’s PCS12852 program is […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2022 Results Conference Call
August 8, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has scheduled a conference call and webcast to discuss its second-quarter 2022 results; company executives will also provide an update on PCSA’s clinical pipeline during […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Launches New Website Focused on Rare Disease
August 4, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has released a new website: Necrobiosislipoidicastudy.com. Through the new website, the company is working to increase awareness of ulcerative Necrobiosis Lipoidica (“uNL”), an extremely rare […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) CEO to Present at World Orphan Drug Congress USA
July 12, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions, has announced that its CEO Dr. David Young will present at the World Orphan Drug Congress USA 2022 Conference. Dr. Young’s presentation, “Thinking Regulatory First – Considerations for the Effective […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2022 Report, Updates
May 13, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, is reporting its financial results for the quarter ended March 31, 2022; the company also released an update on its clinical programs. According to the […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q1 2022 Results, Provide Drug Development Update
May 5, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on May 12, 2022, to discuss its results for the first quarter and provide an […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Administers First Dosage in Amended Phase 1B Study
April 20, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, has started its amended maximum-tolerated dose (“MTD”) phase 1B trial for Next Generation Capecitabine, or the combination of PCS6422 and capecitabine. The company announced that the first patient, who […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Enrolls First Patient in PCS12852 Phase 2A Trial
April 5, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it has enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis. A chronic gastric motility disorder in which […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Year-End 2021 Financial, Corporate Results
March 31, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve survival and/or quality of life, has reported its financial numbers and corporate highlights for 2021 year end. Highlights of the report included the success of the company’s next-generation capecitabine Phase 1B […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q4 2021 Results, Provide Clinical Pipeline Update
March 23, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on March 30, 2022, to discuss its fourth quarter 2021 results and provide an […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) CEO to Present at Oppenheimer 32nd Annual Healthcare Conference
March 10, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that its CEO Dr. David Young will present at the Oppenheimer 32nd Annual Healthcare Conference. Dr. Young’s presentation is slated to begin at 10:00 a.m. Eastern Time on […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Issues Letter to Shareholders Eyeing ‘Transformative Year’ in 2022
January 26, 2022
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today released a letter to shareholders from its Chief Executive Officer Dr. David Young. In the letter, Dr. Young shared 2021 accomplishments and the company’s […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q3 2021 Financial, Corporate Results
November 12, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve survival and/or quality of life, has reported its financial numbers and corporate highlights for third quarter 2021. Included in the report was results of the company’s next-generation capecitabine phase 1B trial, […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Results of Next-Generation Capecitabine Analysis
November 4, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has released information regarding its next-generation capecitabine study. According to the company, the next-generation capecitabine dosage regimen, which is a combination of PCS6422 administered with capecitabine, successfully inhibited dihydropyrimidine dehydrogenase […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Q3 Results, Development Update Call
October 26, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it will report financial results for the quarter ended Sept. 30, 2021, on Thursday, Nov. 11, 2021. According to the update, the company will host a conference call […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Key Milestone in Clinical Develop Program for PCS12852
October 12, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it has been cleared by the U.S. Food and Drug Administration (“FDA”) to proceed with a phase 2a clinical trial of PCS12852. The trial will study PCS12852 in […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Investor Conferences
September 16, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that management will participate in upcoming investor conferences. According to the update, PCSA will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit starting at 9:05 a.m. […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at World Orphan Drug Congress USA
August 24, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, will be presenting at the World Orphan Drug Congress USA Conference. The three-day event is scheduled for Aug. 25-27. Processa CEO and chair Dr. David Young will be the company […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q2 Earnings, Schedules Earnings Call
August 13, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has announced its financial results for Q2 2021, the quarter ended June 30, 2021. The company also shared a corporate update. Highlights of the report include that Processa dosed its […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Aug. 12 Earnings, Update Conference Call
August 6, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has scheduled a conference call to discuss its Q2 results and to provide an update on its drug development pipeline. The call is scheduled for Aug. 12, 2021, at 5:30 […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Gastrointestinal Cancer Study Dosing Has Begun
August 4, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has dosed the first patient in its PCS6422 study. The study is a phase 1b dose-escalation evaluation of the safety and pharmacokinetics of fixed-dose PCS6422 with escalating doses of capecitabine administered […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at ‘Zooming with LD Micro’
July 27, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event. Processa’s presentation is scheduled to begin at 12:00 p.m. ET on Thursday, July 29, […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Plans Presentation at Unique Access to Giving Virtual Investor Conference
July 6, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, is slated to present at the upcoming Access to Giving virtual conference. The conference is scheduled for July 14, 2021; PCSA’s presentation will begin at 10:30 a.m. ET. PCSA CEO […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate in Access to Giving Virtual Investor Conference
June 23, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, will participate in the Access to Giving investor conference. The conference, scheduled for July 13–15, 2021, is the first of its kind focused on investor education and advocacy. More than […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Strategic Licensing Agreement
June 17, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has entered into a licensing agreement with Ocuphire Pharma Inc. (NASDAQ: OCUP). Under the agreement, Processa has an exclusive worldwide license (excluding China) to develop, manufacture, use, commercialize and sublicense […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Join Russell Microcap(R) Index
June 9, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, announced that it is set to join the Russell Microcap(R)Index. The company noted that it is scheduled to make the move at the conclusion of the 2021 Russell indexes annual […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming LD Micro Virtual Investor Conference
June 8, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, will participate in the LD Micro Virtual Investor Conference. The conference is slated for June 9, 2021. PCSA management will present during the conference. PCSA’s actual presentation is scheduled as […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Investor Conferences
May 26, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has announced that executive management personnel will be participating in two investor conferences, both scheduled to take place in June. Company officials will be at the Craig-Hallum Virtual Institutional Investor Conference, […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Phase 2 PCS499 Trial Has First Dosed Patient
May 21, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has dosed its first patient in its PCS499 trial; the dosing took place at the Clinical Research Center of the Carolinas. The trial, which is currently enrolling patients, is designed […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Investor Conferences
May 19, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has announced that key management personnel will participate in two upcoming investor conferences. PCSA executives will present at the Oppenheimer Rare & Orphan Disease Summit, which is scheduled for May […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2021 Financial, Corporate Report
May 14, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial and corporate results for the first quarter of 2021, the period ended March 31, 2021. In the report, PCSA noted that its clinical drug pipeline is […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference/Webcast to Discuss Q1 Results, Provide Clinical Pipeline Update
May 7, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that it will host a conference call and live webcast to discuss its first quarter 2021 results and provide an update on its clinical pipeline. The event is […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases FY 2020 Financial, Corporate Report
March 26, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial numbers for the year ending Dec. 31, 2020; the company also reported a corporate update. High on the list of noteworthy achievements for the year 2020 […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Conference Call to Discuss Q4 Numbers, Clinical Pipeline Update
March 22, 2021
Processa Pharmaceuticals Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has scheduled a conference call to discuss its fourth-quarter financial report as well as to provide a drug-development update. The conference call and life webcast will be available to […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Sites for Phase 2B Clinical Trial
March 17, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announced that it has selected five U.S. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for the company’s Phase 2B trial. In […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes $10.2M Private Placement
March 2, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has closed its previously announced private placement to institutional and accredited investors. According to the update, the company sold 1,321,132 shares of its common stock at a purchase price of […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report
February 22, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://ibn.fm/NqQs7. The report reads, “Processa’s pipeline is […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Executes Purchase Agreement to Raise $10.2M
February 17, 2021
Processa Pharmaceuticals Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has executed a securities purchase agreement. The agreement is intended to raise gross proceeds of $10.2 million through the sale of 1,321,132 shares. The shares will be sold at […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at H.C. Wainwright BIOCONNECT 2021
January 11, 2021
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. According to the update, the presentation is now available for on-demand listening by visiting https://ibn.fm/OVOdD. In […]
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report
December 10, 2020
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by the Benchmark Company LLC. The report, titled “Processa Pharmaceuticals Inc. (PCSA) Processing Assets to the FDA; Initiate at Buy,” lists a $15 price […]